Lung Cancer Dispatch
Follow
Find tag "carboplatin"
3.6K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Helix BioPharma Corp. Receives U.S. Food and Drug Administration Approval to Initiate a Clinical Trial of L-DOS47 in Combination With Pemetrexed and Carboplatin

Helix BioPharma Corp. Receives U.S. Food and Drug Administration Approval to Initiate a Clinical Trial of L-DOS47 in Combination With Pemetrexed and Carboplatin | Lung Cancer Dispatch | Scoop.it

"Helix BioPharma Corp. (frankfurt:HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the U.S. Food and Drug Administration ("FDA"), to initiate a Phase I clinical trial with L-DOS47.


"The study is entitled "A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer"."


Editor's note: Clinical trials can be a way for some lung cancer patients to access certain treatments they would not otherwise be able to have. Learn more.

Cancer Commons's insight:

MarketWatch  |  Apr 22, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Motesanib Plus Carboplatin, Paclitaxel Extended Survival in NSCLC

Motesanib Plus Carboplatin, Paclitaxel Extended Survival in NSCLC | Lung Cancer Dispatch | Scoop.it

"The addition of motesanib to carboplatin and paclitaxel improved OS, PFS and response rates in patients with nonsquamous non–small cell lung cancer, according to results of a phase 3 study.


"The subset analysis of the MONET1 trial included 227 Asian patients with stage IIIb/IV or recurrent disease who had not received prior systemic therapy for advanced NSCLC."

Cancer Commons's insight:

Healio  |  Feb 13, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Four-Drug Combination Shown to Be Safe and Effective for NSCLC

Four-Drug Combination Shown to Be Safe and Effective for NSCLC | Lung Cancer Dispatch | Scoop.it

A combination of the drugs carboplatin (Paraplatin), paclitaxel (Taxol/Abraxane), cetuximab (Erbitux), and bevacizumab (Avastin) has demonstrated effectiveness against non-small cell lung cancer (NSCLC) in a phase II clinical trial. One hundred two patients with advanced non-squamous NSCLC received the four-drug combo as a first-line treatment. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Patients went an average of 7 months without their cancer progressing; the average survival time was 15 months. Four treatment-related deaths occurred, including two due to hemorrhage (heavy bleeding), which can be a rare but serious effect of Avastin treatment. This side effect profile was within the predefined safety margin. A phase III trial further investigating this drug combination for NSCLC is currently enrolling participants.

Cancer Commons's insight:

MedwireNews  |  Dec 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

The makers of lorvotuzumab mertansine (IMGN901) have halted a clinical trial investigating the use of the drug in extensive-stage small-cell lung cancer (SCLC). An independent monitoring group recommended ending the trial because patients treated with IMGN901 in addition to the chemotherapy agents etoposide (Etopophos) and carboplatin (Paraplatin) fared no better than patients treated with Etopophos and Paraplatin only. Furthermore, the patient group receiving IMGN901 appeared to have higher rates of infections and infection-related deaths, with at least one death potentially related to IMGN901.

Cancer Commons's insight:

Yahoo! Finance | Nov 5, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Cancer Drug Reolysin Shrinks Lung Tumors

Interim results from a phase II clinical trial of the new cancer drug Reolysin in squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer (NSCLC), show that tumors shrank in 23 of 25 patients. The patients had SCC that had spread from its original site, or recurred after treatment, and were treated with the chemotherapy drugs Paraplatin (carboplatin) and Taxol/Abraxane (paclitaxel) in addition to Reolysin. Ten patients experienced tumor shrinkage and 13 experienced stable disease, while the cancer progressed in 2 patients. On average, tumors shrank by a third of their original size. Reolysin consists of a modified form of a virus that selectively attacks cancer cells, while producing no symptoms in most healthy people.

Cancer Commons's insight:

Businessweek | Sep 9, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Chemotherapy-Tarceva Combination May Be Effective for Some Lung Cancer Patients

Chemotherapy-Tarceva Combination May Be Effective for Some Lung Cancer Patients | Lung Cancer Dispatch | Scoop.it

Results from the FASTACT clinical trial suggest that interspersing erlotinib (Tarceva) among rounds of chemotherapy improves outcomes in non-small cell lung cancer (NSCLC). Patients with advanced NSCLC received six cycles of gemcitabine (Gemzar) plus carboplatin (Paraplatin) or cisplatin (Platinol), with Tarceva added during the second half of each chemotherapy cycle. This regimen prolonged time without cancer worsening and increased survival compared to patients who had received chemotherapy and placebo, though the benefit was only seen in patients with mutations in the EGFR gene. This approach may be most useful for patients whose EGFR status is unknown, as patients with known EGFR mutations may be even better served by first-line treatment with Tarceva alone.

Cancer Commons's insight:

Healio | Jul 10, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Comparison of Combination Chemotherapy Regimens Shows No Significant Differences

Both pemetrexed (Alimta) plus carboplatin (Paraplatin) and Paraplatin plus paclitaxel (Taxol/Abraxane) plus bevacizumab (Avastin) are effective chemotherapy regimens against non-small cell lung cancer (NSCLC). However, until recently, the safety and efficacy of the two regimens had not been directly compared. To evaluate whether one regimen was superior, a phase III clinical trial determined how long patients with advanced non-squamous NSCLC remained free of either cancer progression or severe toxic side effects when treated with either of the two regimens. While patients receiving the Alimta plus Paraplatin regimen tended to have slightly longer relapse- and toxicity-free periods than those given Paraplatin plus Taxol/Abraxane plus Avastin, the difference was not very pronounced and could have happened by chance. The two regimens also did not differ regarding overall time until cancer progression, response rate and overall survival time.

Cancer Commons's insight:

CancerNetwork | June 6, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Alimta-Paraplatin Combination Appears to Be Effective Treatment for Elderly Lung Cancer Patients

Alimta-Paraplatin Combination Appears to Be Effective Treatment for Elderly Lung Cancer Patients | Lung Cancer Dispatch | Scoop.it

Most elderly patients with advanced non-small cell lung cancer (NSCLC) do not receive chemotherapy and no age-specific guidelines for choosing chemotherapy agents exist. A phase II clinical trial investigated treatment with pemetrexed (Alimta) and carboplatin (Paraplatin) for elderly (aged 70+ years) patients with advanced NSCLC and little functional impairment. The combination treatment was as effective in these patients as it had been in younger populations in previous studies and more effective than single-agent chemotherapy. While some patients experienced serious side effects, especially blood-related complications, overall toxicity was acceptable, suggesting that combined Alimta and Paraplatin may be a viable treatment option for similar patients.

Cancer Commons's insight:

Lung Cancer | Feb 25, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

CHFR Protein Levels Predict Effectiveness of Chemotherapy

CHFR Protein Levels Predict Effectiveness of Chemotherapy | Lung Cancer Dispatch | Scoop.it

A study of patients with advanced non-small cell lung cancer (NSCLC) given chemotherapy with carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane) found that patients with lower levels of the protein CHFR were more likely to respond to the treatment and survived longer than patients with high CHFR levels. These findings suggest that CHFR levels could be a useful biomarker for indicating patients likely to respond to so-called taxane chemotherapy drugs like Taxol, Abraxane, or docetaxel (Taxotere). In the future, treatments that target CHFR may be developed to increase responsiveness to taxane chemotherapy in patients with high CHFR levels.

Cancer Commons's insight:

Clinical Cancer Research | Feb 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Abraxane-Paraplatin Combination May be Safe and Effective in Elderly Patients with Advanced Lung Cancer

A recent study examined first-line treatment with the chemotherapy agent carboplatin (Paraplatin) combined with either albumin-bound paclitaxel (Abraxane) or standard solvent-based paclitaxel (Taxol) in both elderly and younger patients with advanced non-small cell lung cancer (NSCLC). Patients treated with Abraxane/Paraplatin exhibited higher treatment response rates and fewer toxic side effects in both age groups, and elderly patients (age 70+ years) experienced longer periods without cancer progression and longer overall survival with Abraxane/Paraplatin compared to Taxol/Paraplatin treatment. Abraxane plus Paraplatin may constitute a safe, effective first-line treatment for elderly patients with advanced NSCLC, a group that has been traditionally undertreated.


Research paper: http://annonc.oxfordjournals.org/content/24/2/314.long

Cancer Commons's insight:

Annals of Oncology | Nov 2, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Pilot Study of New SCLC Drug Offers Encouragement

Preliminary trial results indicate that a new drug, IMGN901, enhances standard etoposide/carboplatin treatment in some small cell lung cancer (SCLC) patients. IMGN901 targets cells that express the protein CD56—a hallmark of nearly all SCLC tumors. ImmunoGen, Inc. will further investigate the SCLC treatment potential of IMGN901 in the large-scale NORTH trial.

Cancer Commons's insight:

equities.com | Sep 11, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer

"AbbVie (ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo."


Editor's note: Clinical trials are used to test new cancer treatments. Enrolling in a clinical trial might give a patient access to a promising treatment he/she would otherwise not be able to receive. Learn more about lung cancer clinical trials here.

Cancer Commons's insight:

Yahoo! Finance  |  Apr 15, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Novel Immune-Based Cancer Drug Imprime PGG Appears Effective in Certain Lung Cancer Patients

Novel Immune-Based Cancer Drug Imprime PGG Appears Effective in Certain Lung Cancer Patients | Lung Cancer Dispatch | Scoop.it

Adding the drug Imprime PGG to chemotherapy and antibody therapy may be effective for certain patients with non-small cell lung cancer (NSCLC). Imprime PGG contains a molecule called beta glucan, which can stimulate the body’s immune cells to destroy cancer cells. This process may be especially effective in patients with high levels of immune system proteins that bind to beta glucan, so-called antibeta glucan antibodies. In a recent clinical trial, patients with advanced NSCLC received the antibody drug cetuximab (Erbitux) and the chemotherapy agents carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane), and some were also given Imprime PGG. While survival across all patients was not affected by Imprime PGG treatment, it was increased in Imprime PGG-treated patients with high levels of antibeta glucan antibodies. Seventeen percent of these patients survived 3 years or more, while none of the other patient groups did.

Cancer Commons's insight:

Medical Xpress  |  Jan 8, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective | Lung Cancer Dispatch | Scoop.it

Combining cetuximab (Erbitux), bevacizumab (Avastin), and traditional chemotherapy in patients with non-small cell lung cancer (NSCLC) appeared to be safe and effective in a phase II clinical trial. Patients with advanced non-squamous NSCLC received Erbitux and Avastin in addition to carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane) as first-line treatment, followed by maintenance treatment with Erbitux and Avastin. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Serious side effects were relatively rare; the rate was comparable to that of either Erbitux or Avastin alone. Both Erbitux and Avastin have shown efficacy in NSCLC by themselves, but may be more effective when given together. An ongoing phase III clinical trial will further investigate this drug combination.

Cancer Commons's insight:

Medical News Today | Nov 5, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Alimta Offers Only Limited Advantage in Lung Cancer Study

The recent PointBreak clinical trial compared two treatment regimens for non-squamous non-small cell lung cancer (NSCLC). Previously untreated patients with advanced non-squamous NSCLC received initial treatment with carboplatin (Paraplatin), bevacizumab (Avastin), and either pemetrexed (Alimta) or paclitaxel (Taxol/Abraxane). The Alimta-treated group was then given maintenance treatment with Alimta and Avastin, while the other patients received Avastin only. Alimta treatment was associated with slightly longer times until the cancer progressed again (average 6.0 months, compared to 5.6 in the Alimta-free regimen). However, overall survival did not differ between the groups. The two regimens differed in what specific side effect were most common, but had similar overall toxicities and were generally tolerable.

Cancer Commons's insight:

MedPage Today | Oct 21, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Trial of New Lung Cancer Drug OGX-427 Now Enrolling Participants

Trial of New Lung Cancer Drug OGX-427 Now Enrolling Participants | Lung Cancer Dispatch | Scoop.it

The Spruce trial, a phase II clinical trial examining the effectiveness of the cancer drug OGX-427 in non-small cell lung cancer (NSCLC), is now open for enrollment. The trial will study patients with previously untreated, advanced non-squamous NSCLC. They will receive the chemotherapy agents carboplatin (Paraplatin) and pemetrexed (Alimta) in combination with either OGX-427 or a placebo. The sponsors also plan to add the Cedar trial, which will investigate the use of OGX-427 in squamous cell NSCLC. OGX-427 inhibits Hsp27, a protein that is highly expressed in many tumor cells. The drug may be especially promising for patients without mutations that make them eligible for currently available targeted therapies.


Cancer Commons's insight:

MarketWatch | Aug 1, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Adding Paraplatin to Alimta Increases Survival in Lung Cancer Study

Adding Paraplatin to Alimta Increases Survival in Lung Cancer Study | Lung Cancer Dispatch | Scoop.it

Results from a phase III clinical trial suggest that adding carboplatin (Paraplatin) to pemetrexed (Alimta) can improve outcomes in non-small cell lung cancer (NSCLC). Over 200 patients with advanced NSCLC received first-line treatment with Alimta either by itself or in combination with Paraplatin. The combination of the two chemotherapy agents extended the time before the cancer started growing again, and prolonged survival compared to Alimta alone. However, the combination treatment group had a higher incidence of serious side effects and four treatment-associated deaths.

Cancer Commons's insight:

Healio | June 24, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Clinical Trial of Drug OGX-427 Aims to Help Patients Ineligible for Targeted Therapies

OncoGenex Pharmaceuticals announced that it will begin the Spruce clinical trial, a phase II study investigating the use of their cancer drug OGX-427 in non-small cell lung cancer (NSCLC). Patients with advanced non-squamous NSCLC will receive first-line treatment with chemotherapy using carboplatin (Paraplatin) and pemetrexed (Alimta), either with or without the addition of OGX-427. OGX-427 inhibits a protein called Hsp27, which is elevated in many cancers. The study investigators suggest that OGX-427 may be especially helpful for patients whose cancers lack certain mutations that would make them eligible for currently available targeted therapies.

Cancer Commons's insight:

Pharmaceutical Business Review | Apr 12, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Reolysin Shrinks Lung Cancer Tumors in Clinical Trial

A phase II study of the novel cancer treatment Reolysin in 20 patients with advanced squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer, showed a reduction in tumor size in 95% of patients. Patients were given Reolysin in combination with the chemotherapy drugs carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane); on average, their tumors shrank by about a third. This finding suggests that Reolysin may be useful for presurgical treatment of tumors. Reolysin, made by the company Oncolytics, is a form of a virus called reovirus. Most adults have been exposed to reovirus, which usually does not produce symptoms. However, reovirus selectively infects and kills tumor cells.


Press release: http://www.oncolyticsbiotech.com/news_items/details?press_release_id=1921

Cancer Commons's insight:

Reuters | Feb 8, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Conatumumab Does Not Appear to Benefit Patients with Advanced Lung Cancer

Conatumumab is an antibody (a type of immune system protein) that targets TR-2, a protein that is expressed in tumor tissue in a variety of cancer types. A phase II study of patients with previously untreated advanced non-small cell lung cancer (NSCLC) receiving either conatumumab or placebo in combination with standard paclitaxel (Taxol)-carboplatin (Paraplatin) chemotherapy showed that conatumumab was well tolerated, but did not improve clinical outcomes. However, it is possible that in patients selected for relevant biomarkers, conatumumab may show effectiveness that is not seen in an unselected patient population.

Cancer Commons's insight:

Journal of Thoracic Oncology | Jan 29, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

FDA Approves Abraxane for Treatment of Advanced NSCLC

FDA Approves Abraxane for Treatment of Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

The FDA has approved the use of breast cancer drug Abraxane in conjunction with carboplatin for non-small cell lung cancer (NSCLC) treatment. Abraxane, manufactured by Celgene Corp., combines paclitaxel with a protein called albumin. Earlier this year, a large clinical trial found Abraxane plus carboplatin to be more effective in shrinking advanced NSCLC tumors than the standard paclitaxel drug Taxol plus carboplatin. Abraxane treatment may be particularly effective for patients with squamous NSCLC patients age 70 years or older and North American patients.

Cancer Commons's insight:

Huffington Post | Oct 12, 2012

more...
No comment yet.